CAR‑T immunotherapy — in which a patient’s own T cells are removed from their body, reprogrammed in the lab to target and destroy cancer cells, and then reintroduced — has saved the lives of thousands of leukemia, lymphoma, and myeloma patients. But the procedure is slow, expensive, and hazardous. Umoja is developing a vector that delivers RNA instructions for the needed cancer-targeting receptors directly into the bloodstream, potentially lowering the risks and costs of cancer treatment and generating lasting remissions.
News & Insights
Explore Companies
Radionetics Oncology
Discovering more precise ways to deploy radiopharmaceuticals against solid tumors
Fourth Power
Building thermal energy storage technology to buffer the grid, as variable electricity sources replace polluting ones
Reality Defender
Stopping deepfakes before they become a problem
DVLP Medicines
Creating a software co-pilot for drug development and a new marketplace for investors and outsourced R&D and manufacturing